Preclinical data for transdermal drug
(cz) Pantec Biosolutions reports promising preclinical in vitro data in support of the company’s novel Please intraepidermal drug delivery platform.
Pantec Biosolutions has achieved further important milestones in the replacement of injection-based therapies with painless needle-free transdermal systems In vitro permeation proof-of-principle studies with a series of small and large molecular weight therapeutics, demonstrate that Please (painless laser epidermal system) significantly increases drug transport of poorly and non-permeating therapeutic agents.
Proof-of-principle, according to Yogeshvar Kalia, (school of pharmaceutical sciences, University of Geneva and scientific advisor to Pantec Biosolutions), “means cumulative drug permeation that is at least equivalent to delivery from the existing dosage form, e.g, by subcutaneous injection”.
The company has completed in vitro permeation studies with several key hormones in its primary focus area of in vitro fertilisation (IVF).
The results formed the basis of collaboration agreements with a pharmaceuticals company and a patch development and manufacturing company.
Development of transdermal patch systems, optimised for use with the Please technology, is underway with clinical results expected in 2009. more…
From: »laboratorytalk«